The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has updated information on its web site (https://www.senesco.com/; obtained on 3-18-12) since last reported on in The Hygiology Post on September 18, 2011. As a matter of disclosure : The author continues to be a current shareholder in the company.
Currently, statements on its “Home” web page include :
“HELPING TO CURE CANCER AND FEED THE WORLD”,
“REGULATING CELL DEATH AND SURVIVAL. INNOVATIVE SOLUTIONS TO CELL SURVIVAL.” and
“Senesco is a cancer therapeutics company employing its strong proprietary platform in eukaryotic translation initiation Factor 5A (eIF5A) technology to regulate cell death and survival. The Company’s is lead therapeutic candidate SNS01-T incorporates recent developments in siRNA, DNA regulation and nanotechnology. Senesco is building its portfolio with other potential eiF5A applications in cancer, inflammation and ischemia.”
The company is currently engaged in “Clinical Trials” :
“Senesco is sponsoring a Phase 1b/2a clinical trial of SNS01-T for patients with multiple myeloma who have relapsed from, or failed to respond to, at least two previous treatment regimens. For contact information, please visit the study page on clinicaltrials.gov.”
The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2012 The Hygiology Post